Intuitive(ISRG)

Search documents
Vessel Sealer Curved receives FDA clearance
Globenewswire· 2025-07-10 13:15
Core Insights - Intuitive has received FDA clearance for its latest advanced energy instrument, the Vessel Sealer Curved, designed for use with its multiport da Vinci systems [1][2] - The Vessel Sealer Curved is the first of Intuitive's advanced energy instruments cleared for the transection of lymphatic vessels, enhancing its multifunctionality and precision [2][4] Product Features - The Vessel Sealer Curved features a slim, curved jaw that follows anatomical contours, improving visibility and control in tight spaces [3] - It is designed for grasping, blunt dissection of tissue, bipolar coagulation, and mechanical transection of blood vessels up to 7mm in diameter, as well as lymphatic vessels [4] Company Background - 2025 marks the 30th anniversary of Intuitive in developing robotic-assisted technology, with nearly 17 million da Vinci procedures performed and around 90,000 surgeons trained [5] - Intuitive aims to improve patient outcomes, enhance care team experiences, increase access to minimally invasive care, and reduce treatment costs [5][6] Technology Overview - The da Vinci surgical systems provide high-definition 3D vision and robotic assistance, enabling precise dissection and reconstruction during minimally invasive surgeries [7]
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
ZACKS· 2025-07-08 13:31
Core Insights - Intuitive Surgical (ISRG) has achieved a 15% year-over-year increase in da Vinci system installations, surpassing 10,000 units globally, with 367 systems placed in Q1 2025, including 147 next-gen da Vinci 5 systems, driven by strong U.S. demand [1][10] - Recurring revenues constitute 85% of total revenues, with overall procedures growing 17% year-over-year; however, average system utilization increased only 2%, indicating a potential issue with return on investment for hospitals [2][3] - The limited growth in core platform utilization raises concerns about hospital ROI post-installation, prompting management to focus on training and digital adoption to enhance throughput [3][4] Competitive Landscape - Stryker (SYK) reported record Mako installations in Q1 2025, driven by strong demand in orthopedics, with high utilization rates particularly in knee and hip procedures [5] - Stryker plans to launch Mako Spine later in 2025 and Mako Shoulder in early 2026, aiming to expand its robotic offerings across specialties [6] - Zimmer Biomet's (ZBH) ROSA robotics platform is seeing ongoing adoption in knee procedures, although results are more muted compared to competitors; the system is central to ZBH's robotic strategy for 2025 [7][8] Financial Performance - ISRG shares have gained 2.4% year-to-date, contrasting with a 7.7% decline in the industry [9] - The forward price-to-earnings ratio for ISRG stands at 64.35, above the industry average but lower than its five-year median of 72.21, with a Value Score of D [12] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 6.8% increase from the previous year [13]
ISRG da Vinci 5 Gets European Nod: Will it Boost the Stock's Prospect?
ZACKS· 2025-07-07 13:50
Core Insights - Intuitive Surgical (ISRG) received CE-mark approval for its latest surgical robot system, da Vinci 5, which includes over 150 enhancements aimed at improving surgical outcomes and operational efficiency [1][2] - The da Vinci 5 system is cleared for minimally invasive endoscopic procedures across various specialties, expanding Intuitive Surgical's clinical reach in Europe [2][7] - The surgical robots market in Europe is projected to grow from $1.89 billion in 2024 to $3.31 billion by 2030, with a CAGR of 10.3% from 2025 to 2030, driven by technological innovation and increasing chronic conditions [4] Company Developments - The da Vinci 5 system offers 10,000 times more processing power than earlier generations, integrating advanced sensors and software for real-time insights to improve surgeon performance [3] - In Q1 2025, 147 out of 367 da Vinci systems placed globally were da Vinci 5 units, indicating strong demand in the U.S. market [5][7] - The adoption of force feedback instruments in da Vinci 5 procedures has shown significant clinical benefits, including faster recovery times and improved surgical proficiency [5] Market Performance - Intuitive Surgical's performance in Europe remains strong, with 88 earlier versions of da Vinci systems placed in Q1 2025, and over 410,000 procedures performed in 2024 [8] - Despite macroeconomic pressures, the company continues to focus on training and operational optimization to support procedural growth [8][14] - ISRG's stock has gained 18.9% over the past three months, outperforming the industry average of 14.3% [10] Competitive Landscape - Intuitive Surgical faces competition from companies like Medtronic and Stryker, with Medtronic's Hugo system being 20-25% less expensive but noted for a steeper learning curve [9] - Stryker's Hugo leads in orthopedic robotic surgery, indicating a segmented competitive landscape [9] Financial Outlook - The Zacks Consensus Estimate for ISRG's earnings per share has been revised downwards for 2025 and 2026, reflecting rising costs associated with the launch of da Vinci 5 [6] - ISRG is currently trading at a forward price-to-earnings multiple of 64.32X, higher than the industry average of 28.81X, but lower than its five-year median [15] Long-Term Prospects - The CE mark approval for da Vinci 5 opens significant revenue potential in Europe's growing surgical robotics market [15] - Despite near-term challenges, ISRG's dominant market share and focus on innovation position it well for long-term growth [15]
2 Unstoppable Growth Stocks to Hold for the Next 20 Years
The Motley Fool· 2025-07-05 15:10
Group 1: Microsoft - Microsoft is a leader in operating software for personal and business computing, with significant contributions to total revenue and earnings [2] - The company's primary growth driver is its cloud computing business, Microsoft Azure, where it ranks second only to Amazon [3][5] - Microsoft generated $69.4 billion in free cash flow over the trailing-12-month period, and its investments in artificial intelligence (AI) are expected to enhance earnings and stock performance [6] - The company has increased its dividend payouts by almost 168% in the past decade, although its forward yield is 0.7%, lower than the S&P 500 average of 1.3% [7] Group 2: Intuitive Surgical - Intuitive Surgical has dominated the robotic-assisted surgery (RAS) market for the past two decades with minimal competition, leading to strong financial results [8] - The company benefits from switching costs, as healthcare facilities invest significant resources in training and equipment, making them reluctant to switch to competitors [9][10] - The RAS market has substantial growth potential, with less than 5% of eligible surgeries performed robotically, and demand is expected to rise as the population ages [10][11] - Intuitive Surgical continues to innovate, having launched the fifth generation of its da Vinci system and integrated AI into its features, positioning it well for future growth [11][12]
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028
The Motley Fool· 2025-07-04 07:51
Core Insights - The rapid rise of Palantir Technologies in the AI sector may be temporary, with concerns about its high valuation and market sustainability [5][8][7] AI Market Overview - The global addressable market for AI is projected to reach $15.7 trillion by 2030, indicating significant growth potential for various companies [2] Palantir Technologies - Palantir's stock has surged by 1,940% since the beginning of 2023, leading to a market cap exceeding $300 billion [5] - The company has a sustainable competitive advantage with its Gotham and Foundry platforms, which are difficult for competitors to replicate [6] - Palantir's business model includes multiyear government contracts and an enterprise-based subscription model, contributing to predictable cash flow [6] - Despite its strengths, Palantir faces historical challenges that have affected other tech companies, including potential overvaluation and negative investor sentiment [7] - Palantir's price-to-sales (P/S) ratio is currently above 104, significantly higher than the historical range of 30 to 43 for leading companies in similar trends, suggesting an unsustainable valuation [8] Competitors with Growth Potential - Pfizer, with a current market cap of $142 billion, is positioned to grow stronger, especially with its oncology segment bolstered by the acquisition of Seagen [10][13] - PayPal, valued at $73 billion, offers a more attractive risk-reward profile with sustained double-digit growth potential and a forward price-to-earnings ratio of 13 [16][20] - Intuitive Surgical, with a market cap of $193 billion, dominates the robotic-assisted surgical market and is expected to see revenue growth driven by higher-margin services and accessories [21][25]
Intuitive's da Vinci 5 Surgical System Receives CE Mark
GlobeNewswire News Room· 2025-07-02 13:46
Core Insights - Intuitive Surgical has received CE mark approval for its da Vinci 5 Surgical System for both adult and pediatric use in Europe, enabling minimally invasive endoscopic procedures [1][3] - The da Vinci 5 is the most advanced multiport robotic-assisted surgical system, featuring over 150 enhancements and building on the design of the da Vinci Xi Surgical System [2][4] - The da Vinci surgical systems have been utilized in over 410,000 procedures in Europe in 2024 and nearly 17 million procedures globally to date [2][7] Company Developments - The da Vinci 5 Surgical System is designed to improve surgical outcomes, efficiency, and provide actionable insights for healthcare systems [4][8] - Intuitive has been developing robotic-assisted technology for 30 years, with nearly 90,000 surgeons trained worldwide [7] - The da Vinci 5 system offers enhanced surgical capabilities, including advanced 3D vision, ergonomic design, and operational efficiencies [8][10] Market Impact - The introduction of the da Vinci 5 provides surgeons in Europe with greater choice and flexibility, supporting quality care for more patients [5][6] - The system aims to address critical challenges faced by healthcare systems across Europe, potentially transforming surgical practices [4][5]
Intuitive’s da Vinci 5 Surgical System Receives CE Mark
Globenewswire· 2025-07-02 13:46
Core Insights - The da Vinci 5 Surgical System has received CE mark approval for use in Europe, allowing for minimally invasive endoscopic procedures in both adult and pediatric patients [1][3] - This system is the most advanced in the da Vinci series, featuring over 150 enhancements and has been utilized in more than 410,000 procedures in Europe in 2024 and nearly 17 million procedures globally [2][7] Company Overview - Intuitive is a leader in minimally invasive care and robotic-assisted surgery, celebrating its 30th year of developing such technologies [7][9] - The company aims to improve patient outcomes, enhance the experience for patients and care teams, increase access to minimally invasive care, and reduce treatment costs [7][9] Product Features - The da Vinci 5 system includes advanced features such as Force Feedback technology, a high-definition 3D vision system, and an ergonomic surgeon console [8] - It offers operational efficiencies through greater surgeon autonomy and a streamlined workflow, making it easier for care teams to use [8] - The system is powered by an intelligent platform with significantly enhanced computing capabilities, providing actionable insights for surgical performance improvement [8] Market Impact - The introduction of the da Vinci 5 system is expected to transform surgical practices and address challenges faced by healthcare systems in Europe [4][5] - Surgeons and care teams will have access to a full portfolio of da Vinci systems, enhancing choice and flexibility in surgical options [5][6]
Can ISRG Maintain Robotics Edge Amid Rising Rivalry & Budget Strain?
ZACKS· 2025-07-01 13:11
Core Insights - Intuitive Surgical (ISRG) reported a strong first-quarter 2025 performance, with revenues increasing by 19% year-over-year to $2.25 billion and earnings per share (EPS) exceeding expectations [1][9] - The company has installed over 10,000 global systems and is witnessing growing adoption of the da Vinci 5 system, but it is facing structural challenges such as increased competition and reduced hospital capital expenditures [1][9] Financial Performance - Revenues for Q1 2025 reached $2.25 billion, marking a 19% increase compared to the previous year [1][9] - Recurring revenues constitute 85% of total revenues, indicating a stable revenue stream [2] - Gross margins are forecasted to be in the range of 65-66.5% for the full year 2025, impacted by tariffs and higher depreciation costs [2] Competitive Landscape - Intuitive Surgical is encountering rising competition, particularly from Medtronic (MDT) and Globus Medical (GMED) [4][5] - Medtronic's Hugo system is seeking FDA clearance, which could introduce significant competition in the U.S. market for minimally invasive surgery (MIS) robotics [4] - Globus Medical's ExcelsiusGPS platform is gaining traction in spinal and cranial procedures, showcasing its capabilities at GSC 2025 [5][6] Technological Edge - The company's ecosystem, which includes proven outcomes, clinical training, and an AI-enhanced surgical suite, provides a competitive advantage [3] - The da Vinci 5 system's force feedback tools are demonstrating clinical value, with studies indicating improved patient recovery and reduced surgeon error [3] Strategic Considerations - To maintain its market leadership, Intuitive Surgical must adapt to price-sensitive buyer behavior by leveraging leasing models and optimizing the utilization of installed systems [7] - The company’s long-term success will depend on navigating value-based purchasing and global reimbursement dynamics [7] Stock Performance and Valuation - ISRG shares have increased by 4.1% year-to-date, contrasting with a 9% decline in the industry [8] - The forward price-to-earnings ratio for Intuitive Surgical is 64.35, which is above the industry average but lower than its five-year median of 72.21 [11] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 6.8% increase from the previous year [12]
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
ZACKS· 2025-06-25 13:16
Core Insights - Intuitive Surgical (ISRG) demonstrated strong operational momentum entering 2025, with a 17% year-over-year growth in da Vinci procedures and a 19% increase in total revenues to $2.25 billion in Q1 [1][9] - Management raised full-year guidance for procedure growth to 15-17%, supported by robust adoption in general surgery in the U.S. and accelerated utilization in emerging markets [1][9] - The rollout of the da Vinci 5 platform continued effectively, with 147 new systems placed and over 32,000 procedures completed using the new-generation robot [1] Financial Performance - Gross margins declined to 66.4% in Q1 from 67.6% a year ago, attributed to increased depreciation, a higher mix of lower-margin platforms, and cost pressures from global tariffs [2][9] - ISRG expects tariff-driven costs to erode margins by approximately 170 basis points for the full year, revising gross margin forecast to 65-66.5% [2] Revenue Composition and Challenges - Recurring revenues remain strong, accounting for 85% of total revenues, but capital expenditures and rising input costs may challenge operating leverage [3] - Constrained hospital budgets in key markets like Germany and Japan could impact the company's capital placement run rate, adding further margin pressure [3] Market Context - While ISRG's procedure growth and market adoption are commendable, they face challenges from tightening margins, macroeconomic headwinds, and evolving trade dynamics [4] - Investors should monitor whether strong volume momentum can continue to offset inflationary and structural cost pressures in the upcoming quarters [4] Competitor Analysis - Stryker (SYK) reported organic sales growth of 10.1% and total revenues of $5.87 billion, with a gross margin of 65.5%, up 190 basis points year-over-year [5][6] - Medtronic (MDT) achieved 3.9% year-over-year revenue growth to $8.93 billion, with a gross margin improvement to 64.7% [7] Valuation Metrics - ISRG shares have gained 0.1% year-to-date, contrasting with the industry's decline of 11.4% [8] - The company trades at a forward price-to-earnings ratio of 62.09, above the industry average but lower than its five-year median of 72.17 [10] - The Zacks Consensus Estimate for ISRG's 2025 earnings implies a 6.8% rise from the previous year [12]
最新!达芬奇老将加入单孔机器人公司
思宇MedTech· 2025-06-23 08:23
Core Viewpoint - The appointment of Jim Alecxih as CEO of Virtual Incision marks a significant leadership change aimed at advancing the commercialization of the MIRA surgical robot platform and the development of next-generation products [1][4]. Group 1: Leadership Change - Jim Alecxih has over 30 years of experience in the medical device industry and is recognized for his leadership in surgical robotics [4]. - Alecxih previously held a key role at Intuitive Surgical, where he contributed to the widespread adoption of the da Vinci surgical robot in U.S. hospitals [4]. - His leadership is expected to drive innovation and market adoption of Virtual Incision's technology, which is seen as forward-looking and adaptable to various surgical scenarios [4]. Group 2: MIRA Surgical Robot - The MIRA platform is a miniaturized robotic system designed for laparoscopic surgery, featuring a portable design that does not require dedicated space or infrastructure [7]. - MIRA consists of a micro arm, a supporting cart, and a surgeon's console, with the micro arm weighing approximately 2 pounds (900 grams) and capable of performing minimally invasive surgeries [7]. - The system includes a high-definition camera with automatic tracking capabilities, optimized for multi-quadrant surgeries [7]. Group 3: Clinical Applications - MIRA is primarily used for laparoscopic surgeries, allowing surgeons to access the abdominal cavity through small incisions [14]. - The platform's application range is expanding to include hernia repair, gallbladder removal, and other abdominal surgeries, having received FDA's Investigational Device Exemption (IDE) for clinical research [15]. Group 4: Company Background - Virtual Incision was founded in 2006 as a spin-off from the University of Nebraska-Lincoln and is known for developing the world's first small robotic-assisted surgery (RAS) platform [16]. - The company aims to accelerate the development of the next-generation M2 system, which is designed to reduce the cost and complexity of existing large surgical robots [16].